Atomoxetine

In a four-week, double-blind, placebo-controlled within-subject pilot study with 18 healthy volunteers, atomoxetine 40 mg was tested for its ability to attenuate physiological and subjective responses to standardized stress procedures and oral d-amphetamine, aiming to characterize its impact on stress reactivity and stimulant responses.

In six healthy adults with a history of nontherapeutic stimulant use, atomoxetine (15–90 mg) produced some dose-dependent stimulant-like subjective effects and modest cardiovascular changes but only partially substituted for methylphenidate and showed low abuse-related behavioral effects.

In a four-week, double-blind, placebo-controlled within-subject pilot study with 18 healthy volunteers, atomoxetine 40 mg was tested for its ability to attenuate physiological and subjective responses to standardized stress procedures and oral d-amphetamine, aiming to characterize its impact on stress reactivity and stimulant responses.

In six healthy adults with a history of nontherapeutic stimulant use, atomoxetine (15–90 mg) produced some dose-dependent stimulant-like subjective effects and modest cardiovascular changes but only partially substituted for methylphenidate and showed low abuse-related behavioral effects.

In adults with ADHD treated with atomoxetine for up to four years, the drug maintained symptom improvement and showed a generally acceptable safety profile, with common adverse effects including dry mouth, insomnia, and gastrointestinal complaints, informing expectations for long-term tolerability.

An integrated analysis of 15 randomized, placebo-controlled trials in adults with ADHD found that atomoxetine significantly improved ADHD symptom scores versus placebo and was generally well tolerated, with adverse effects such as nausea, dry mouth, and insomnia more frequent than with placebo.

This pilot study included methamphetamine-abusing individuals and healthy controls aged 18–50 years, examining how atomoxetine influenced cardiovascular parameters, cognition, and subjective effects when combined with intravenous methamphetamine, providing data on autonomic responses and tolerability in part of a healthy population.

In six healthy adults with a history of nontherapeutic stimulant use, atomoxetine (15–90 mg) produced some dose-dependent stimulant-like subjective effects and modest cardiovascular changes but only partially substituted for methylphenidate and showed low abuse-related behavioral effects.

This pilot study included methamphetamine-abusing individuals and healthy controls aged 18–50 years, examining how atomoxetine influenced cardiovascular parameters, cognition, and subjective effects when combined with intravenous methamphetamine, providing data on autonomic responses and tolerability in part of a healthy population.

In six healthy adults with a history of nontherapeutic stimulant use, atomoxetine (15–90 mg) produced some dose-dependent stimulant-like subjective effects and modest cardiovascular changes but only partially substituted for methylphenidate and showed low abuse-related behavioral effects.

In adults with ADHD treated with atomoxetine for up to four years, the drug maintained symptom improvement and showed a generally acceptable safety profile, with common adverse effects including dry mouth, insomnia, and gastrointestinal complaints, informing expectations for long-term tolerability.

An integrated analysis of 15 randomized, placebo-controlled trials in adults with ADHD found that atomoxetine significantly improved ADHD symptom scores versus placebo and was generally well tolerated, with adverse effects such as nausea, dry mouth, and insomnia more frequent than with placebo.

In adults with ADHD treated with atomoxetine for up to four years, the drug maintained symptom improvement and showed a generally acceptable safety profile, with common adverse effects including dry mouth, insomnia, and gastrointestinal complaints, informing expectations for long-term tolerability.

An integrated analysis of 15 randomized, placebo-controlled trials in adults with ADHD found that atomoxetine significantly improved ADHD symptom scores versus placebo and was generally well tolerated, with adverse effects such as nausea, dry mouth, and insomnia more frequent than with placebo.